List of Excipients in Branded Drug CONTEPO

Company	Tradename	Ingredient	NDC	Excipient	Potential Generic Entry
Meitheal Pharmaceuticals Inc	CONTEPO	fosfomycin disodium	71288-035	SUCCINIC ACID	2033-10-22

CONTEPO Excipient Strategy and Commercial Opportunities

Last updated: August 4, 2026

CONTEPO is the proposed intravenous formulation of fosfomycin disodium, developed by Nabriva Therapeutics for serious bacterial infections, including complicated urinary tract infections and infections caused by multidrug-resistant pathogens. Its commercial opportunity depends less on discovering a new excipient than on solving delivery problems associated with high-dose intravenous fosfomycin: sodium burden, reconstitution, infusion volume, stability, compatibility, and hospital workflow.

CONTEPO did not receive FDA approval. The FDA issued a complete response letter in December 2020, citing deficiencies at a third-party manufacturing facility. Because no U.S. approval was granted, CONTEPO has no FDA-approved prescribing information, no commercial U.S. excipient declaration, and no Orange Book listing. [1]

What is CONTEPO and why does its excipient profile matter?

CONTEPO is an intravenous fosfomycin product based on fosfomycin disodium. Fosfomycin is a small-molecule antibiotic with activity against a broad range of Gram-positive and Gram-negative bacteria, including some resistant organisms. Its intravenous use requires substantially greater exposure than the single-dose oral fosfomycin products used for uncomplicated urinary tract infections.

The principal formulation issues are:

Formulation issue	Commercial consequence
High daily dose	Increases sodium exposure and infusion burden
Fosfomycin disodium salt	Active ingredient contributes sodium independently of excipients
Powder for reconstitution	Creates preparation steps and medication-error risk
Aqueous instability risk	Limits shelf life after reconstitution or dilution
High infusion volumes	Raises nursing time, storage and administration costs
Compatibility requirements	Affects diluent choice, tubing, containers and co-administration
Hospital use	Rewards ready-to-use and pharmacy-efficient presentations

Excipient design therefore has a direct effect on product positioning. A formulation that reduces preparation time, limits particulate or precipitation risk, and provides predictable post-reconstitution stability could gain value even if it does not materially change fosfomycin’s antibacterial activity.

What excipients are known or likely to be used in CONTEPO?

The exact final CONTEPO excipient composition cannot be treated as publicly established because the product did not receive an FDA-approved label. The active pharmaceutical ingredient is fosfomycin disodium. Any additional excipients would need to be confirmed from regulatory filings, manufacturing documentation, or an approved product label.

A conventional sterile fosfomycin powder may require a limited excipient system because the drug is administered as a solution after reconstitution. Potential excipient functions include pH adjustment, tonicity control, buffering, stabilization and protection during lyophilization.

Likely excipient functions

Function	Candidate approach	Strategic assessment
pH control	Sodium hydroxide, hydrochloric acid or a buffer system	Must avoid excess sodium and preserve stability
Tonicity	Sodium chloride or other tonicity agent	May increase total sodium load
Buffering	Phosphate, citrate or acetate systems	Can create compatibility and precipitation concerns
Lyophilization support	Mannitol or similar bulking agent	May improve cake structure and reconstitution
Stabilization	Minimal formulation or selected polyol	Depends on degradation pathway
Container protection	Low-extractable vial, stopper and seal system	Important for storage and reconstitution integrity
Premix presentation	Diluted solution in a flexible bag	Can reduce pharmacy labor but increases stability demands

A key distinction is that sodium from fosfomycin disodium is not an excipient problem. It is part of the active salt. Adding sodium chloride, sodium phosphate or other sodium-containing excipients can increase the total sodium exposure and weaken the product’s hospital value proposition.

How does sodium burden affect the CONTEPO commercial strategy?

Sodium burden is one of the most important formulation constraints for intravenous fosfomycin. High-dose treatment can expose patients to a clinically relevant sodium load, particularly when the product is reconstituted or diluted with sodium chloride injection.

The commercial formulation should therefore prioritize:

1. The lowest practical concentration of sodium-containing excipients.
2. Compatibility with dextrose-based diluents where clinically appropriate.
3. Clear sodium-content disclosure by vial, dose and treatment day.
4. A dosing presentation that reduces unnecessary dilution volume.
5. Hospital guidance for patients with heart failure, renal impairment or sodium-restricted diets.

A formulation that uses sodium chloride solely to create isotonicity may be less attractive than one that achieves acceptable administration characteristics through concentration, controlled pH and a compatible low-sodium diluent. This does not eliminate the active ingredient’s intrinsic sodium contribution, but it can avoid compounding the burden.

What formulation patents could protect CONTEPO?

Potential patent protection for CONTEPO would likely fall into several categories:

Composition and formulation claims

These may cover:

• Fosfomycin disodium at a defined concentration.
• Specific pH ranges.
• Particular buffer or tonicity systems.
• Stabilized aqueous formulations.
• Lyophilized compositions with defined reconstitution performance.
• Low-sodium or reduced-excipient formulations.
• Defined impurity limits or degradation profiles.

Container and delivery claims

Protection may also cover:

• Vial and stopper combinations.
• Ready-to-use infusion bags.
• Dual-chamber containers.
• Reconstitution devices.
• Closed-system transfer components.
• Compatibility with selected administration sets.

Method-of-use claims

Method patents could address:

• Intravenous fosfomycin dosing schedules.
• Treatment of complicated urinary tract infections.
• Treatment of hospital-acquired or ventilator-associated infections.
• Use against resistant Enterobacterales.
• Combination therapy with beta-lactams or other antibiotics.
• Renal-adjusted dosing regimens.

A formulation patent is commercially valuable only if it covers a product configuration that hospitals prefer and competitors cannot readily design around. Broad claims to fosfomycin disodium alone are less likely to provide meaningful protection because the active substance is old and widely known.

What is the Orange Book status of CONTEPO?

CONTEPO has no FDA Orange Book listing because it was not approved in the United States. As a result:

• There is no approved reference listed drug entry for CONTEPO.
• There are no Orange Book patent listings for the product.
• There is no statutory Hatch-Waxman exclusivity period attached to an approved CONTEPO NDA.
• There is no conventional ANDA Paragraph IV pathway against an approved CONTEPO reference product.
• Any future U.S. sponsor would need to address the applicable regulatory pathway based on the eventual NDA status and product history.

The absence of an Orange Book listing does not mean that all intellectual-property barriers have disappeared. Unexpired formulation, manufacturing, use or process patents could still create litigation risk. They would need to be assessed independently from Orange Book status.

When does CONTEPO lose exclusivity?

CONTEPO has no operative U.S. market exclusivity because it did not receive FDA approval. The product therefore has no confirmed U.S. approval date, five-year new-chemical-entity exclusivity period, three-year clinical-investigation exclusivity period, or pediatric exclusivity period.

The underlying fosfomycin molecule is old. Commercial protection would therefore depend on:

• Product-specific formulation patents.
• Manufacturing and sterile-processing patents.
• Method-of-use patents.
• Regulatory exclusivity associated with any future approval.
• Trade secrets involving impurity control, crystallization, sterilization or packaging.
• Contractual rights held by the sponsor or licensees.

In Europe and other jurisdictions, the analysis would depend on local approvals and patent families. U.S. regulatory status cannot be used as a proxy for global exclusivity.

Which excipient strategies create the strongest commercial opportunities?

1. Ready-to-use intravenous bags

A ready-to-use bag could eliminate vial reconstitution and reduce pharmacy compounding time. The main technical hurdle is maintaining chemical and microbiological stability throughout the labeled shelf life.

Commercial advantages include:

• Lower preparation labor.
• Reduced handling and reconstitution errors.
• Faster administration in urgent-care settings.
• Easier use in intensive-care and antimicrobial-stewardship protocols.
• Better standardization across hospitals.

The disadvantages are greater shipping weight, larger cold-chain or controlled-storage requirements if needed, and a more difficult stability program.

2. Dual-chamber presentations

A dual-chamber container could separate concentrated fosfomycin from the diluent until administration. This approach may provide a compromise between powder vials and fully premixed bags.

Potential benefits include:

• Longer shelf life before activation.
• Reduced pharmacy manipulation.
• More consistent final concentration.
• Lower risk of premature degradation.

The presentation would require device-development work, container-closure studies and human-factors validation.

3. High-concentration reconstituted powder

A high-concentration vial can reduce final infusion volume. This may be valuable for patients who require fluid restriction and for hospitals managing high infusion volumes.

The formulation must control:

• Reconstitution time.
• Foaming.
• Particulate formation.
• Final pH.
• Osmolality.
• Stability in the selected diluent.
• Compatibility with commonly used infusion systems.

4. Low-sodium excipient system

A low-sodium system could differentiate CONTEPO from formulations that add sodium chloride or sodium-based buffers. This opportunity is commercially meaningful in patients with renal dysfunction, cardiac disease or strict sodium limits.

The value proposition should be based on total sodium per administered dose, not merely the absence of sodium chloride as an excipient.

5. Compounding-optimized vial

A simpler and potentially lower-risk strategy is to improve the conventional vial rather than pursue a complex delivery device. Product attributes could include:

• Rapid dissolution.
• Minimal vial hold-up volume.
• Clear reconstitution instructions.
• Broad diluent compatibility.
• Longer in-use stability.
• Reduced particulate risk.
• Standardized dose sizes.

This approach may be more practical for hospital procurement if it delivers measurable labor savings without increasing acquisition cost.

How strong is the patent estate for a new CONTEPO formulation?

The patent position is likely strongest where the formulation solves a specific technical problem and produces measurable performance benefits. Examples include improved stability, reduced sodium load, shorter reconstitution time or extended compatibility in a ready-to-use container.

A weak patent position would rely on:

• Fosfomycin disodium as a general active ingredient.
• Routine use of common buffers.
• Broad claims to standard intravenous administration.
• Known diluents without an unexpected stability result.
• Unclaimed hospital workflow advantages.

A stronger portfolio would combine:

Patent layer	Purpose
Core formulation patent	Protects composition and concentration
Stability patent	Protects shelf life and in-use stability
Device patent	Protects dual-chamber or ready-to-use presentation
Method patent	Protects dosing and patient populations
Manufacturing patent	Protects impurity control and sterile processing
Trade secret	Protects process parameters and scale-up know-how

Patent term should be modeled from each family’s earliest nonprovisional or international filing date, with terminal disclaimers and patent-term adjustment assessed separately. No expiration date should be assigned without a verified patent-family review.

What manufacturing and IP barriers affect commercialization?

Manufacturing is a material barrier for CONTEPO because sterile injectable products require validated aseptic processing, container-closure integrity and robust commercial-scale controls. The FDA’s 2020 complete response letter linked to third-party manufacturing deficiencies highlights the importance of the manufacturing platform in the product’s regulatory risk. [1]

Key barriers include:

• Reliable supply of pharmaceutical-grade fosfomycin disodium.
• Control of related substances and degradation products.
• Reproducible crystallization or drying.
• Sterile filtration or aseptic filling.
• Lyophilization-cycle robustness, if a powder presentation is used.
• Container-closure compatibility.
• Scale-up without changes in reconstitution or stability.
• Validation of the commercial manufacturing site.
• Supply continuity for specialized bags, stoppers or delivery devices.

The regulatory history increases the value of a qualified manufacturing network. A future sponsor would need to demonstrate that the facility, process and quality system can support the proposed dosage form.

What generic entry risks exist for CONTEPO?

Because CONTEPO lacks U.S. approval, conventional generic entry cannot proceed against an approved U.S. reference product under the normal commercial framework. If a future product is approved, entry risks could include:

• A competing fosfomycin injection under a separate NDA.
• A 505(b)(2) product relying in part on published literature or an existing fosfomycin product.
• A generic or hybrid application if the regulatory reference and dosage form support that pathway.
• Competing hospital-compounded preparations.
• Imported or regionally approved fosfomycin products.
• Alternative antibiotics used in the same resistant-infection treatment protocols.

The most defensible commercial position would combine a differentiated presentation with enforceable formulation or device claims. A standard vial of an old active ingredient is more exposed to price competition.

How does CONTEPO compare with competing intravenous antibiotics?

CONTEPO would compete with established intravenous agents used against resistant Gram-negative infections, including ceftazidime-avibactam, meropenem-vaborbactam, imipenem-cilastatin-relebactam, cefiderocol, aminoglycosides and polymyxins.

Attribute	CONTEPO opportunity	Competitive implication
Mechanism	Distinct bacterial cell-wall target	Useful in selected resistance settings
Active ingredient age	Old molecule	Limits composition-of-matter protection
IV formulation	High-dose administration	Creates sodium and workflow challenges
Resistance profile	Potential activity against difficult pathogens	Must be supported by susceptibility and clinical data
Formulation differentiation	Ready-to-use, low-sodium or high-stability product	Could support premium positioning
Hospital economics	Potential reduction in compounding labor	Important where acquisition price is high
Regulatory status	No U.S. approval	Major commercial disadvantage versus approved competitors

CONTEPO’s strongest market position would likely be as a targeted hospital antibiotic rather than a broad first-line product. A pharmacy-friendly presentation could support formulary adoption where clinicians value a non-beta-lactam option or where resistance limits alternatives.

What licensing deals and ownership issues affect CONTEPO?

Nabriva Therapeutics was the principal developer associated with CONTEPO. The product’s commercial potential is affected by rights to:

• Fosfomycin injection patents.
• Clinical and regulatory dossiers.
• Manufacturing agreements.
• Drug-master-file access.
• Regional commercialization.
• Data and market exclusivity.
• Trademark rights to CONTEPO and related product names.

No licensing arrangement should be assumed to transfer all of these rights. A transaction review should distinguish patent ownership, NDA ownership, manufacturing rights, territorial licenses and rights to regulatory correspondence.

The absence of U.S. approval may reduce upfront valuation but can create an opportunity for a specialty-pharma buyer with an established sterile-injectable platform. The asset is more likely to attract a partner with hospital sales infrastructure, infectious-disease expertise and manufacturing remediation capability than a conventional oral-generic company.

What revenue exposure could a CONTEPO launch create?

Revenue depends on pricing, treatment duration, pathogen targeting, hospital contracting and competition from established antibiotics. A high-value launch would require evidence that the product reduces one or more of the following:

• Length of hospital stay.
• Pharmacy preparation time.
• Need for combination therapy.
• Use of nephrotoxic rescue antibiotics.
• Treatment failure in resistant infections.
• Infusion-related logistical costs.

The commercial model should segment demand into:

1. Complicated urinary tract infections.
2. Bloodstream infections caused by resistant organisms.
3. Hospital-acquired infections.
4. Salvage therapy for patients with limited options.
5. Combination regimens guided by susceptibility testing.

A ready-to-use or reconstitution-optimized product could command a premium only if the sponsor quantifies labor, waste and administration savings. Antibiotic stewardship programs may limit unrestricted use, making clinical differentiation and formulary evidence essential.

What is the likely generic launch scenario?

The most plausible U.S. launch scenarios are:

Scenario	Timing driver	Risk to innovator
No relaunch	Manufacturing or funding failure	Asset remains commercially dormant
Relaunch with original vial	Successful regulatory remediation	Moderate price competition
Relaunch with improved formulation	New approval and patent protection	Stronger differentiation
505(b)(2) competitor	Published data and formulation development	Potentially rapid competition
Hospital-compounded use	Limited commercial availability	Price and quality pressure
Regional launch outside U.S.	Local approval and supply access	Fragmented geographic competition

A differentiated formulation offers the clearest route to defensible value. The active ingredient alone is unlikely to sustain a durable premium.

Key Takeaways

• CONTEPO is an investigational intravenous fosfomycin disodium product associated with Nabriva Therapeutics.
• The FDA issued a complete response letter in December 2020; CONTEPO has no U.S. approval or Orange Book listing. [1]
• The central excipient issues are sodium burden, pH control, stability, reconstitution and infusion compatibility.
• Fosfomycin disodium itself contributes sodium, so sodium-free excipients do not eliminate the total sodium concern.
• The strongest commercial formulation opportunities are ready-to-use bags, dual-chamber systems, high-concentration vials and compounding-optimized powders.
• Product-specific formulation, device, manufacturing and method-of-use patents would matter more than composition-of-matter protection.
• Generic entry risk is unusual because no approved U.S. reference product currently supports a conventional CONTEPO ANDA challenge.
• Commercial success would require regulatory remediation, reliable sterile manufacturing and clear hospital-economic value.

FAQs

Does CONTEPO contain sodium chloride?

The publicly established active ingredient is fosfomycin disodium. The final commercial excipient composition was not established through an FDA-approved U.S. label. Sodium chloride should not be assumed to be present or absent without verified product documentation.

Is CONTEPO the same as oral fosfomycin tromethamine?

No. CONTEPO was developed as an intravenous fosfomycin disodium product, while oral fosfomycin tromethamine is used primarily as a single-dose treatment for uncomplicated urinary tract infection.

Could a ready-to-use CONTEPO bag receive separate patent protection?

Yes. A ready-to-use bag could support device, formulation, stability, container-closure or method claims if the claims satisfy novelty, nonobviousness and enablement requirements.

Can hospitals compound intravenous fosfomycin instead of purchasing CONTEPO?

Hospital-compounded preparations may be possible under applicable pharmacy and regulatory rules, but they do not create an equivalent commercial product. Stability, sterility, quality control, sourcing and institutional policy would determine practical use.

Would a future CONTEPO approval receive new chemical entity exclusivity?

That outcome cannot be assumed. Fosfomycin is an old active ingredient, and the exclusivity available for a future submission would depend on the statutory pathway, approved product status and FDA determinations.

References

1. U.S. Food and Drug Administration. (2020, December 21). Nabriva Therapeutics plc receives complete response letter from FDA for CONTEPO. FDA regulatory communications and company announcement materials.